In the afternoon, Quanxin Biopharmaceutical-B (02509) experienced a significant 10% increase in volume and a 4.25% rise, trading at HKD 24.55 with a turnover of HKD 2.1389 million at the time of publication.
According to the Wise Money APP, Quanxin Biopharmaceutical-B (02509) experienced a significant 10% increase in volume in the afternoon, and at the time of publication, it had risen 4.25%, trading at HKD 24.55 with a turnover of HKD 2.1389 million.
On the news front, Quanxin Biopharmaceuticals announced that the Phase II clinical trial data of QX005N Injection for the treatment of Prurigo Nodularis (PN) was orally presented at the 29th Chinese Association of Dermatology Annual Meeting. Based on the trial data, QX005N was listed as a breakthrough treatment on January 31st of this year by the National Medical Products Administration’s Drug Evaluation Center.
It is reported that this trial is the first clinical trial of a biological drug for PN indications conducted by a domestic enterprise in China. The research results show that the main endpoints of each dose group in this clinical trial were fully met.